Intragastric Balloon Market

Intragastric Balloon Market Size (2024 to 2029)

The global intragastric balloon market size is valued at USD 160.69 Million in 2024 and is anticipated to reach USD 256.44 Million by 2029 with a CAGR of 9.8% during the forecast period.

The Intragastric balloon method is a weight-loss procedure where a saline-filled silicone balloon is placed in the stomach, which helps to lose weight. It works by limiting the quantity of food taken to feel full faster. It is a temporary procedure which does not require any surgery. The balloon placed stays in the stomach for six months, and then it is removed. Similar to other weight loss procedures, the intragastric balloon procedure also requires a commitment to a healthy, balanced diet and exercise for the long-term success of the procedure. Weight gain leads to major chronic health complications, which is a major concern for people, making them choose the intragastric balloon procedure for weight loss.

Market Drivers:

The rising prevalence of obesity among people across the globe is majorly contributing to the global intragastric balloon market growth. According to WHO statistics, around 2.7 billion population will be overweight, and around 1 billion are estimated to be obese by 2025. WHO also states that around 2.8 million people die each year due to obesity or overweight. This high mortality is expected to increase demand for weight-loss methods such as intragastric balloons, which are practical and minimally invasive procedures—the growing demand for minimally invasive procedures across the population due to practical and lower complications. According to an NCBI research article in 2022, in the studied population, around 57% of the patients preferred minimal invasive treatment due to health professionals' influence, and they reported fewer perceived disadvantages of the treatment. These factors boost the growth of the global intragastric balloon market. The American Society for Metabolic and Bariatric Surgery included intragastric balloons in the list of procedures and devices as the treatment option. According to a National Center for Biotechnology Information study published in 2023, intragastric balloons are minimally invasive tools to combat the obesity pandemic. The United States and European Markets approve multiple intragastric balloons. These kinds of government initiatives and approvals from regulatory authorities fuel market revenue growth. 

The growing technological advancements in the balloon design and functionality over the past decade, which allows the balloon to stay in the stomach for 12 months, and the improved features like smooth surface, collapsibility, and addition of gauge ports enhanced the safety outcomes. These advancements are propelling the growth of global market revenue. The increasingly favorable reimbursement policies from the government and insurance sectors are enhancing the adoption of intragastric balloon procedures and fueling the market value.

The growing investments in R&D to develop balloons with minimal adverse effects to support patient comfort will create market growth opportunities during the forecast period. There is an increasing demand for combination therapies where, along with intragastric balloons, other anti-obesity interventions are utilized to enhance the weight loss process, which is expected to give rapid and effective results. Growing collaborations and acquisitions among the market players and pharmaceuticals supporting digital health are estimated to boost the market expansion in the upcoming years.

Market Restraints:

The side effects produced by the intragastric balloon procedure, such as abdominal pain, temporary sore throat, nausea, indigestion, acid reflux, and constipation, are hampering the adoption rate, which is impacting the market growth. Most people experience discomfort during the process, which is more impactful than acute pain, produced during the first week of the procedure, and is manageable by the medications. Few patients experience persistent gastrointestinal symptoms where the pain stays beyond one week and cannot be relieved by the medications. Other factors such as hyperinflation, deflation, acute pancreatitis, and stomach ulcers are infrequent scenarios that lead to the early removal of the balloon. All these reasons are hindering the market value growth of the intragastric balloon technique.

The challenge for market expansion worldwide is the need for more awareness among the people and healthcare professionals in developing countries where intragastric balloons are a weight loss option. Most manufacturers need to educate the people and healthcare providers of developing countries regarding the advantages of the procedure to increase adoption, which is challenging for the manufacturers. Even though the procedure costs less than the surgery, it is still difficult to afford for people from low economic backgrounds. The low reimbursement policies and insurance claims act as barriers to market growth.

Impact of Covid-19 on the Intragastric balloon market:

The Pandemic had a high impact on the intragastric balloons market as obese patients are at higher risk of COVID-19. According to WHO data, in 2020, more than 1.9 billion adults were overweight, and around 650 million of them were obese. According to data published by the CDC in 2021, around 30.2% of total COVID-19 patients are attributed to obesity. This increased the demand for the intragastric balloon procedure during the Pandemic. Various reports state that the rate of obesity had increased during the Pandemic due to changes in lifestyle and a decrease in exercise because of the closure of gyms by lockdown.

REPORT COVERAGE:

This research report on the global intragastric balloon market is segmented and sub-segmented based on animal type, Administration, Filling Material, End-use, and region.

By Type:

• Single 
• Dual
• Triple

The single intragastric balloon segment held the largest revenue share of 74% in 2023 due to significant weight loss by this product, and high availability is driving the global market in this segment. This segment is projected to dominate the forecast period with significant revenue due to its scientific evidence of the safety and efficacy of the product. 

The triple intragastric balloon segment is estimated to have the fastest growth during the forecast period due to its benefits, such as minimal downtime and reversible treatment options, which will increase the demand for this segment's growth. 

By Administration:

• Pill form 
• Endoscopy 

The Endoscopy segment dominated the global market with a significant revenue share of 70.3% in 2023. The endoscopic procedure is minimally invasive and cost-effective compared to surgical procedures. Emerging endoscopic technologies can reproduce a few anatomic modifications during weight loss surgery and are effective. All these factors contribute to market growth. 

The pill form segment is projected to increase with a significant CAGR during the forecast period. As the pill form is non-surgical, reversible treatment, and swallowable, it allows easy ingestion and excretion, which is comfortable for the people and is expected to augment the market growth.  

By Filling Material:

• Saline-filled
• Gas-filled

The saline-filled segment held the largest share of 65% in the global market in 2023 due to high availability and effective results. The gas-filled segment is projected to dominate the global market rapidly due to the increasingly adverse effects of saline-filled balloons. Growing reporting of the adverse effects of saline-filled balloons enhances the adoption of gas-filled intragastric balloons across the population. 

By End-Use:

• Hospitals
• Clinics
• Ambulatory Surgical Centers

The hospital segment dominated the global market revenue with a significant share of 45% in 2023. The availability of skilled health professionals with advanced technology in the medical devices in the hospitals is enhancing the adoption of hospitals by the people in their medical needs. Various weight loss procedures require staying at hospitals, fueling the global market growth in this segment. 

Ambulatory surgical centers are anticipated to witness rapid growth during the forecast period due to their various advantages, such as hospitalization, rising demand for minimally invasive procedures, and treatment options. 

By Region:

• North America
• Europe
• Asia Pacific 
• Latin America
• Middle East and Africa

The North American region dominated the global intragastric balloon market with a market share of 38% in 2023. The increasing prevalence of obesity, availability of advanced technology in the region's healthcare system, and adoption of weight loss treatments are prominent factors driving the market growth in the region. According to the Organization for Economic Co-operation and Development (OECD), in 2021, around 38.2% of the US population will be obese, which is the highest in the world. The presence of prominent market players in the region with key product launches, acquisitions, collaborations, and partnerships is fueling the regional market growth. According to the National Center for Biotechnology Information (NCBI), in 2022, the US healthcare system is moving forward with minimally invasive treatments in hospitals and clinics where minimally invasive procedures are in high demand due to fewer hospital stays. 

The Asia Pacific region is anticipated to account for the significant market growth rapidly during the forecast period. Growing adoption of unhealthy diets and lifestyles, government policies, and reimbursement policies for treatment in the region are significant factors contributing to global market growth. 

Key Market Players:

Apollo Endosurgery, Inc., Obalon Therapeutics, Allurion Technologies, Spatz3, Endalis, MEDSIL, ReShape Medical Lifesciences, Inc., Lexel Medical, Helioscope, Silimed are some of the key market players in the intragastric balloon market.

Recent Market Developments:

• In June 2023, Allurion Technologies, a medical device company, announced its collaboration agreement with Medtronic, a global medical technology and services leader. This collaboration deals with Allurion's swallowable gastric balloon and AI-powered Iris healthcare management through Medtronic's existing sales in Central and Eastern Europe, the Middle East, and Africa. 
• In October 2022, Allurion received approval for its revolutionary gastric balloon technology in Brazil. It is the only intragastric balloon available in Brazil for weight loss that is used routinely and can be removed without surgery or Endoscopy. 
• In January 2022, Apollo Endosurgery, the leader in advanced therapeutic Endoscopy, announced its approval from the US FDA for its Orbera 365 Managed weight loss system, the first intragastric balloon with an indication for weight loss therapy up to 12 months. 
• In June 2021, Spatz3, a new dual intragastric balloon system by Spatz FGIA, a medical device company, received its CE Mark approval. It is designed to stay in the stomach for 12 months, which helps in weight loss.